Scholarlink

Background <p>Facilitating placental transfusion—the transfer of blood from the placenta to the newborn—via delayed cord clamping (DCC) or umbilical cord milking (UCM) at birth has been shown to improve iron stores in healthy term infants and may positively impact long-term neurodevelopmental outcomes. Infants who are non-vigorous at birth and at risk of developing hypoxic-ischemic encephalopathy (HIE) are particularly likely to benefit from placental transfusion. This process may offer neuroprotection by enhancing cardiopulmonary transition, supporting cardiac preload, improving systemic and cerebral perfusion, delivering stem cells and neurotrophic factors, and preventing iron deficiency. While DCC is not currently recommended for non-vigorous term infants requiring immediate resuscitation, UCM offers a viable alternative, as it can be performed quickly.</p> Methods <p>This study is a multicenter, cluster-randomized, crossover-controlled trial comparing UCM with early cord clamping (ECC) in term and late preterm infants who are non-vigorous at birth. The trial will be conducted across seven centers in India. Before the trial begins, each site will be assigned to an initial study arm using a computer-generated randomization scheme. Once 50% of the enrollment is complete, sites will switch to the alternate study arm after a 2-month washout period. The study is designed with sufficient power to assess the composite outcome of death or moderate-to-severe HIE during birth hospitalization and survival without moderate-to-severe neurodevelopmental impairment at 2&#xa0;years of age. Secondary outcomes include survival without moderate-to-severe neurodevelopmental impairment at 1&#xa0;year of age and survival without evidence of brain injury on MRI during the birth hospitalization.</p> Discussion <p>The CORDMILK trial aims to generate critical evidence on whether UCM can improve survival without moderate-to-severe HIE during birth hospitalization and survival without significant neurodevelopmental impairment at 2&#xa0;years of age in late preterm and term neonates who are non-vigorous at birth.</p> Trial registration <p>Clinical Trial Registry–India CTRI/2021/09/036759. Registered on 22/09/2021. ClinicalTrials.Gov number NCT03657394 and NCT03682042.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

CORDMILK: Umbilical Cord Milking versus Early Cord Clamping on short-and long-term outcomes in neonates who are non-vigorous at birth—study protocol of a multi-center, cluster-randomized, crossover-controlled trial

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月17日

查看全文
  • S. Yogeshkumar,
  • Sunil S. Vernekar,
  • Sangappa M. Dhaded,
  • Kiran Talekar,
  • Benjamin E. Leiby,
  • Rebecca Hartman,
  • Yvonne Vaucher,
  • Nitin Chouthai,
  • Meenakshi Girish,
  • Manish Jain,
  • Shuchi Jain,
  • Seema Parvekar,
  • Vinita Jain,
  • Alka Patankar,
  • Milind Suryawanshi,
  • Manish Tiwari,
  • Manjushri Waikar,
  • Nidhi Nashine,
  • Deepali Ambike,
  • Mahesh Asalkar,
  • Rajesh Kulkarni,
  • Sandhya Haribhaktha,
  • Hemraj Narkhede,
  • Sudha Chaudhari,
  • Milind Kamble,
  • Deepti Shrirame,
  • Balchandra Falke,
  • Seema Mehta,
  • Asha Verma,
  • Sunil Gothwal,
  • Shivaprasad S. Goudar,
  • Richard Derman,
  • Anup Katheria,
  • Zubair H. Aghai

摘要

Background

Facilitating placental transfusion—the transfer of blood from the placenta to the newborn—via delayed cord clamping (DCC) or umbilical cord milking (UCM) at birth has been shown to improve iron stores in healthy term infants and may positively impact long-term neurodevelopmental outcomes. Infants who are non-vigorous at birth and at risk of developing hypoxic-ischemic encephalopathy (HIE) are particularly likely to benefit from placental transfusion. This process may offer neuroprotection by enhancing cardiopulmonary transition, supporting cardiac preload, improving systemic and cerebral perfusion, delivering stem cells and neurotrophic factors, and preventing iron deficiency. While DCC is not currently recommended for non-vigorous term infants requiring immediate resuscitation, UCM offers a viable alternative, as it can be performed quickly.

Methods

This study is a multicenter, cluster-randomized, crossover-controlled trial comparing UCM with early cord clamping (ECC) in term and late preterm infants who are non-vigorous at birth. The trial will be conducted across seven centers in India. Before the trial begins, each site will be assigned to an initial study arm using a computer-generated randomization scheme. Once 50% of the enrollment is complete, sites will switch to the alternate study arm after a 2-month washout period. The study is designed with sufficient power to assess the composite outcome of death or moderate-to-severe HIE during birth hospitalization and survival without moderate-to-severe neurodevelopmental impairment at 2 years of age. Secondary outcomes include survival without moderate-to-severe neurodevelopmental impairment at 1 year of age and survival without evidence of brain injury on MRI during the birth hospitalization.

Discussion

The CORDMILK trial aims to generate critical evidence on whether UCM can improve survival without moderate-to-severe HIE during birth hospitalization and survival without significant neurodevelopmental impairment at 2 years of age in late preterm and term neonates who are non-vigorous at birth.

Trial registration

Clinical Trial Registry–India CTRI/2021/09/036759. Registered on 22/09/2021. ClinicalTrials.Gov number NCT03657394 and NCT03682042.